The University of Chicago Header Logo

Connection

Yuan Ji to Dose-Response Relationship, Drug

Back to Details
This is a "connection" page, showing publications Yuan Ji has written about Dose-Response Relationship, Drug.
Yuan Ji
Connection Strength
1.207
Dose-Response Relationship, Drug
  1. Risk-group-specific dose finding based on an average toxicity score. Biometrics. 2010 Jun; 66(2):541-8.
    View in: PubMed
    Score: 0.251
  2. A Multi-Arm Two-Stage (MATS) design for proof-of-concept and dose optimization in early-phase oncology trials. Contemp Clin Trials. 2023 09; 132:107278.
    View in: PubMed
    Score: 0.165
  3. Practical Impact of Modern Dose-Finding Designs When Compared With the 3 + 3 Design: An Editorial. JCO Precis Oncol. 2021 11; 5:1584-1587.
    View in: PubMed
    Score: 0.147
  4. The i3+3 design for phase I clinical trials. J Biopharm Stat. 2020 03; 30(2):294-304.
    View in: PubMed
    Score: 0.126
  5. A Bayesian interval dose-finding design addressingOckham's razor: mTPI-2. Contemp Clin Trials. 2017 07; 58:23-33.
    View in: PubMed
    Score: 0.108
  6. An integrated dose-finding tool for phase I trials in oncology. Contemp Clin Trials. 2015 Nov; 45(Pt B):426-434.
    View in: PubMed
    Score: 0.096
  7. Modified toxicity probability interval design: a safer and more reliable method than the 3 + 3 design for practical phase I trials. J Clin Oncol. 2013 May 10; 31(14):1785-91.
    View in: PubMed
    Score: 0.081
  8. Dose-finding in phase I clinical trials based on toxicity probability intervals. Clin Trials. 2007; 4(3):235-44.
    View in: PubMed
    Score: 0.053
  9. Bayesian dose-finding in phase I/II clinical trials using toxicity and efficacy odds ratios. Biometrics. 2006 Sep; 62(3):777-84.
    View in: PubMed
    Score: 0.051
  10. [Effect of Sudan I, III and IV on proliferation of HepG-2 and SGC-7901]. Huan Jing Ke Xue. 2006 Jun; 27(6):1201-7.
    View in: PubMed
    Score: 0.051
  11. R-TPI: rolling toxicity probability interval design to shorten the duration and maintain safety of phase I trials. J Biopharm Stat. 2019; 29(3):411-424.
    View in: PubMed
    Score: 0.030
  12. The histone deacetylase inhibitor entinostat (SNDX-275) induces apoptosis in Hodgkin lymphoma cells and synergizes with Bcl-2 family inhibitors. Exp Hematol. 2011 Oct; 39(10):1007-1017.e1.
    View in: PubMed
    Score: 0.018
  13. Dose--schedule finding in phase I/II clinical trials using a Bayesian isotonic transformation. Stat Med. 2008 Oct 30; 27(24):4895-913.
    View in: PubMed
    Score: 0.015
  14. Monitoring late-onset toxicities in phase I trials using predicted risks. Biostatistics. 2008 Jul; 9(3):442-57.
    View in: PubMed
    Score: 0.014
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.